EA017985B1 - Способы определения устойчивости рака к ингибиторам гистондеацетилазы - Google Patents

Способы определения устойчивости рака к ингибиторам гистондеацетилазы Download PDF

Info

Publication number
EA017985B1
EA017985B1 EA200900927A EA200900927A EA017985B1 EA 017985 B1 EA017985 B1 EA 017985B1 EA 200900927 A EA200900927 A EA 200900927A EA 200900927 A EA200900927 A EA 200900927A EA 017985 B1 EA017985 B1 EA 017985B1
Authority
EA
Eurasian Patent Office
Prior art keywords
cancer
expression
biomarker genes
expression levels
inhibitor
Prior art date
Application number
EA200900927A
Other languages
English (en)
Russian (ru)
Other versions
EA200900927A1 (ru
Inventor
Джозеф Дж. Багги
Срирам Баласубраманиан
Original Assignee
Фармасайкликс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фармасайкликс, Инк. filed Critical Фармасайкликс, Инк.
Publication of EA200900927A1 publication Critical patent/EA200900927A1/ru
Publication of EA017985B1 publication Critical patent/EA017985B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/143—Multiplexing, i.e. use of multiple primers or probes in a single reaction, usually for simultaneously analyse of multiple analysis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2545/00—Reactions characterised by their quantitative nature
    • C12Q2545/10—Reactions characterised by their quantitative nature the purpose being quantitative analysis
    • C12Q2545/114—Reactions characterised by their quantitative nature the purpose being quantitative analysis involving a quantitation step
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
EA200900927A 2007-01-30 2008-01-30 Способы определения устойчивости рака к ингибиторам гистондеацетилазы EA017985B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88731807P 2007-01-30 2007-01-30
US91185507P 2007-04-13 2007-04-13
PCT/US2008/052540 WO2008095050A1 (en) 2007-01-30 2008-01-30 Methods for determining cancer resistance to histone deacetylase inhibitors

Publications (2)

Publication Number Publication Date
EA200900927A1 EA200900927A1 (ru) 2010-04-30
EA017985B1 true EA017985B1 (ru) 2013-04-30

Family

ID=39674490

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200900927A EA017985B1 (ru) 2007-01-30 2008-01-30 Способы определения устойчивости рака к ингибиторам гистондеацетилазы
EA201201640A EA201201640A1 (ru) 2007-01-30 2008-01-30 Способы определения устойчивости рака к ингибиторам гистондеацетилазы

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201201640A EA201201640A1 (ru) 2007-01-30 2008-01-30 Способы определения устойчивости рака к ингибиторам гистондеацетилазы

Country Status (10)

Country Link
US (3) US7838234B2 (enExample)
EP (2) EP2107911A4 (enExample)
JP (2) JP5670055B2 (enExample)
KR (1) KR101483805B1 (enExample)
CN (1) CN101657217B (enExample)
AU (2) AU2008210421B2 (enExample)
CA (1) CA2677000A1 (enExample)
EA (2) EA017985B1 (enExample)
NZ (1) NZ579048A (enExample)
WO (1) WO2008095050A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9408816B2 (en) 2006-12-26 2016-08-09 Pharmacyclics Llc Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
NZ579048A (en) * 2007-01-30 2012-05-25 Pharmacyclics Inc Methods for determining cancer resistance to histone deacetylase inhibitors
DE102008000715B9 (de) 2008-03-17 2013-01-17 Sirs-Lab Gmbh Verfahren zur in vitro Erfasssung und Unterscheidung von pathophysiologischen Zuständen
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
EP2702173A1 (en) 2011-04-25 2014-03-05 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
WO2012166722A1 (en) * 2011-06-03 2012-12-06 The General Hospital Corporation Treating colorectal, pancreatic, and lung cancer
KR101384667B1 (ko) * 2011-09-09 2014-04-21 강원대학교산학협력단 항암제인 택솔에 대한 민감성 여부를 판명하는 인자로서의 히스톤 탈아세틸화 효소 3의 용도
KR101892788B1 (ko) 2011-09-13 2018-08-28 파마싸이클릭스 엘엘씨 벤다무스틴과 조합된 히스톤 디아세틸라제 억제제의 제제 및 그의 용도
US9670549B2 (en) 2011-11-10 2017-06-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Gene expression signatures of neoplasm responsiveness to therapy
AU2012358803C1 (en) 2011-12-22 2019-12-19 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CN102532298B (zh) * 2012-03-01 2013-11-06 刘林林 与自身抗体特异性结合的abcc3抗原多肽及应用
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
JP2015515279A (ja) * 2012-04-19 2015-05-28 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 治療に反応する患者を同定するバイオマーカーおよびそのような患者の治療
AU2013202506B2 (en) * 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
JP6800750B2 (ja) 2013-08-02 2020-12-16 ファーマサイクリックス エルエルシー 固形腫瘍の処置方法
JP6749589B2 (ja) * 2015-07-31 2020-09-02 国立大学法人北海道大学 抗Ｅｖａ１タンパク質抗体
CN106467914A (zh) * 2015-08-18 2017-03-01 华东理工大学 靶向人TSPAN8基因的siRNA及其应用
US11015226B2 (en) * 2015-10-06 2021-05-25 Ontario Institute For Cancer Research (Oicr) Targeting the histone pathway to detect and overcome anthracyclin resistance
WO2017070441A1 (en) * 2015-10-23 2017-04-27 Icahn School Of Medicine At Mount Sinai Identifying and treating cancer patients who are suitable for a targeted therapy using an hdac6 inhibitor
US10591462B2 (en) 2016-03-03 2020-03-17 Mohammad Abdolahad Electrochemical method and device for detecting the effect of anticancer drugs
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
CN108300783A (zh) * 2017-01-11 2018-07-20 上海易毕恩基因科技有限公司 用于筛选肠癌和/或胃癌的基因标志物的方法、用该方法筛选的基因标志物及其用途
CN106755464A (zh) * 2017-01-11 2017-05-31 上海易毕恩基因科技有限公司 用于筛选肠癌和/或胃癌的基因标志物的方法、用该方法筛选的基因标志物及其用途
US20190046513A1 (en) * 2017-08-10 2019-02-14 Huya Bioscience International, Llc Combination therapies of hdac inhibitors and tubulin inhibitors
CN114908154A (zh) * 2018-09-21 2022-08-16 王赞鑫 与主动脉夹层疾病相关的snp位点及其应用
EP4013494A1 (en) 2019-08-12 2022-06-22 Regeneron Pharmaceuticals, Inc. Macrophage stimulating 1 receptor (mst1r) variants and uses thereof
JP2022552642A (ja) * 2019-10-07 2022-12-19 ヴィラクタ サブシディアリー，インク． 副作用が軽減されたｈｄａｃ治療の調剤
EP3821890A1 (en) * 2019-11-18 2021-05-19 Strumberg, Dirk Pharmaceutical compositions comprising an inhibitor of a histon-deacetylase (hdaci) and an agonist of toll-like-receptor 7 and/or 8 (tlr7 and/or tlr8) and their use in the treatment of cancer
AU2021251439A1 (en) * 2020-04-09 2022-10-06 THESTRA Oy Eplin as a biomarker for cancer
CN120359245A (zh) * 2022-12-16 2025-07-22 韩国原子力研究院 抗tm4sf4人源化抗体及其用途
CN118743746B (zh) * 2024-06-05 2025-06-06 中国农业大学 Clic5基因或clic5蛋白在制备治疗代谢综合征的药物中的应用

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002053775A2 (en) * 2000-12-28 2002-07-11 Epidauros Biotechnologie Ag Identification of genetic determinants of polymorphic cyp3a5 expression
WO2003001212A2 (en) * 2001-06-22 2003-01-03 Burkhard Jansen A method for diagnosing a person having multiple sclerosis
WO2003066892A1 (en) * 2002-02-04 2003-08-14 Epidauros Biotechnologie Ag Polymorphisms in the human gene for tpmt and their use in diagnostic and therapeutic applications
US20030152923A1 (en) * 2001-08-02 2003-08-14 Zohar Yakhini Classifying cancers
WO2003087336A2 (en) * 2002-04-12 2003-10-23 Wyeth Estrogen receptor alpha regulated gene expression, related assays and therapeutics
US20040018540A1 (en) * 2002-06-28 2004-01-29 Hitachi, Ltd. Evaluation method of interferon beta treatment against multiple sclerosis
WO2004081174A2 (ja) * 2003-03-10 2004-09-23 Japan Science And Technology Agency 間葉系幹細胞検出用マーカー及び該マーカーを用いた間葉系幹細胞の識別方法
WO2006097205A2 (de) * 2005-03-14 2006-09-21 Henkel Kommanditgesellschaft Auf Aktien Verfahren zur extrakorporalen analyse von haarfollikelzellen
US20060276547A1 (en) * 2002-03-04 2006-12-07 Bacopoulos Nicholas G Methods of treating cancer with HDAC inhibitors

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794063A (fr) 1972-01-17 1973-07-16 Henkel & Cie Gmbh Anti-inflammatoires pour compositions cosmetiques
EP0084236A3 (en) 1981-12-22 1983-08-03 Fbc Limited Fungicidal heterocyclic compounds and compositions containing them
US5525464A (en) 1987-04-01 1996-06-11 Hyseq, Inc. Method of sequencing by hybridization of oligonucleotide probes
US5202231A (en) 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
WO1989003819A1 (fr) 1987-10-20 1989-05-05 Otsuka Pharmaceutical Co., Ltd. Derives d'acide phenylcarboxylique
GB8810400D0 (en) 1988-05-03 1988-06-08 Southern E Analysing polynucleotide sequences
US5547839A (en) 1989-06-07 1996-08-20 Affymax Technologies N.V. Sequencing of surface immobilized polymers utilizing microflourescence detection
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5045694A (en) 1989-09-27 1991-09-03 The Rockefeller University Instrument and method for the laser desorption of ions in mass spectrometry
EP0430881A3 (en) 1989-11-29 1991-10-23 Ciba-Geigy Ag Photochromic compounds, process for their preparation and their use
JPH03215470A (ja) 1990-01-22 1991-09-20 Suntory Ltd プロピオン酸アミド誘導体，その製造法及びそれを有効成分として含有する除草剤
US5288644A (en) 1990-04-04 1994-02-22 The Rockefeller University Instrument and method for the sequencing of genome
DE4019005C2 (de) 1990-06-13 2000-03-09 Finnigan Mat Gmbh Vorrichtungen zur Analyse von Ionen hoher Masse
DE4124345A1 (de) 1991-07-23 1993-01-28 Gruenenthal Gmbh Substituierte 3,4-dihydronaphthaline, diese verbindungen enthaltende arzneimittel und verfahren zur herstellung dieser verbindungen und arzneimittel
US5324633A (en) 1991-11-22 1994-06-28 Affymax Technologies N.V. Method and apparatus for measuring binding affinity
DE69322266T2 (de) 1992-04-03 1999-06-02 Perkin-Elmer Corp., Foster City, Calif. Proben zusammensetzung und verfahren
US5503980A (en) 1992-11-06 1996-04-02 Trustees Of Boston University Positional sequencing by hybridization
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
DE4327365A1 (de) 1993-08-14 1995-02-16 Boehringer Mannheim Gmbh Verwendung von Phenolen und Phenolderivaten als Arzneimittel mit fibrinogensenkender Wirkung
US5470710A (en) 1993-10-22 1995-11-28 University Of Utah Automated hybridization/imaging device for fluorescent multiplex DNA sequencing
GB9401833D0 (en) 1994-02-01 1994-03-30 Isis Innovation Method for discovering ligands
WO1997027317A1 (en) 1996-01-23 1997-07-31 Affymetrix, Inc. Nucleic acid analysis techniques
GB9507238D0 (en) 1995-04-07 1995-05-31 Isis Innovation Detecting dna sequence variations
US6040139A (en) 1995-09-19 2000-03-21 Bova; G. Steven Laser cell purification system
US5661028A (en) 1995-09-29 1997-08-26 Lockheed Martin Energy Systems, Inc. Large scale DNA microsequencing device
AU2189397A (en) 1996-02-08 1997-08-28 Affymetrix, Inc. Chip-based speciation and phenotypic characterization of microorganisms
US5958957A (en) 1996-04-19 1999-09-28 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
US5777324A (en) 1996-09-19 1998-07-07 Sequenom, Inc. Method and apparatus for maldi analysis
US5953727A (en) 1996-10-10 1999-09-14 Incyte Pharmaceuticals, Inc. Project-based full-length biomolecular sequence database
WO1999005591A2 (en) 1997-07-25 1999-02-04 Affymetrix, Inc. Method and apparatus for providing a bioinformatics database
US6211197B1 (en) 1998-10-07 2001-04-03 Merck Frosst Canada & Co. Prostaglandin receptor ligands
AU6936500A (en) 1999-08-24 2001-03-19 Regents Of The University Of California, The Non-quinoline inhibitors of malaria parasites
US6541661B1 (en) 1999-11-23 2003-04-01 Methylgene, Inc. Inhibitors of histone deacetylase
WO2002030879A2 (en) 2000-09-29 2002-04-18 Prolifix Limited Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors
GB0023983D0 (en) 2000-09-29 2000-11-15 Prolifix Ltd Therapeutic compounds
WO2002032872A1 (fr) 2000-10-20 2002-04-25 Eisai Co., Ltd. Composes a noyau aromatique azote
ITMI20011733A1 (it) 2001-08-07 2003-02-07 Italfarmaco Spa Derivati dell'acido idrossamico inibitori degli enzimi istone deacetilasi, quali nuovi farmaci antiinfiammatori inibenti la sintesi di citoc
ATE526029T1 (de) * 2001-08-21 2011-10-15 Astellas Pharma Inc Medizinische verwendung eines histon-deacetylase- hemmers und verfahren zur beurteilung seiner antitumoralen wirkung
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20030166026A1 (en) * 2002-01-09 2003-09-04 Lynx Therapeutics, Inc. Identification of specific biomarkers for breast cancer cells
WO2003070691A1 (en) 2002-02-21 2003-08-28 Osaka Industrial Promotion Organization N-hydroxycarboxamide derivative
RU2005105696A (ru) 2002-08-02 2005-11-10 Арджента Дискавери Лимитед (Gb) Замещенные тиенилгидроксамовые кислоты в качестве ингибиторов гистондеацетилазы
EP1400806A1 (en) * 2002-09-18 2004-03-24 G2M Cancer Drugs AG The use of molecular markers for the preclinical and clinical profiling of inhibitors of enzymes having histone deacetylase activity
WO2004074478A1 (ja) * 2003-02-19 2004-09-02 Astellas Pharma Inc. ヒストンデアセチラーゼ阻害剤の抗腫瘍効果の予測方法
PT1611088E (pt) 2003-04-07 2009-09-24 Pharmacyclics Inc Hidroxamatos como agentes terapêuticos
KR20060031809A (ko) * 2003-06-09 2006-04-13 더 리젠츠 오브 더 유니버시티 오브 미시간 암 치료 및 진단용 조성물 및 방법
WO2005043161A2 (en) * 2003-11-04 2005-05-12 Roche Diagnostics Gmbh Method for distinguishing leukemia subtypes
CA2549324A1 (en) * 2003-12-12 2005-06-30 Bayer Pharmaceuticals Corporation Gene expression profiles and methods of use
EP1730308A4 (en) * 2004-03-05 2008-10-08 Rosetta Inpharmatics Llc CLASSIFICATION OF BREAST CANCER PATIENTS USING A COMBINATION OF CLINICAL CRITERIA AND INFORMATIVE SKILLS
AU2005267756A1 (en) * 2004-07-30 2006-02-09 Rosetta Inpharmatics Llc Prognosis of breast cancer patients
WO2006138275A2 (en) * 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
NZ579048A (en) * 2007-01-30 2012-05-25 Pharmacyclics Inc Methods for determining cancer resistance to histone deacetylase inhibitors
UY34295A (es) 2011-09-08 2013-04-30 Servier Lab Nuevo esquema de administración de la n-hidroxi -4- {2-[3- (n,ndimetilaminometil)benzofuran -2- ilcarbonilamino]etoxi}benzamida

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002053775A2 (en) * 2000-12-28 2002-07-11 Epidauros Biotechnologie Ag Identification of genetic determinants of polymorphic cyp3a5 expression
WO2003001212A2 (en) * 2001-06-22 2003-01-03 Burkhard Jansen A method for diagnosing a person having multiple sclerosis
US20030152923A1 (en) * 2001-08-02 2003-08-14 Zohar Yakhini Classifying cancers
WO2003066892A1 (en) * 2002-02-04 2003-08-14 Epidauros Biotechnologie Ag Polymorphisms in the human gene for tpmt and their use in diagnostic and therapeutic applications
US20060276547A1 (en) * 2002-03-04 2006-12-07 Bacopoulos Nicholas G Methods of treating cancer with HDAC inhibitors
WO2003087336A2 (en) * 2002-04-12 2003-10-23 Wyeth Estrogen receptor alpha regulated gene expression, related assays and therapeutics
US20040018540A1 (en) * 2002-06-28 2004-01-29 Hitachi, Ltd. Evaluation method of interferon beta treatment against multiple sclerosis
WO2004081174A2 (ja) * 2003-03-10 2004-09-23 Japan Science And Technology Agency 間葉系幹細胞検出用マーカー及び該マーカーを用いた間葉系幹細胞の識別方法
WO2006097205A2 (de) * 2005-03-14 2006-09-21 Henkel Kommanditgesellschaft Auf Aktien Verfahren zur extrakorporalen analyse von haarfollikelzellen

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ammerpohl О. et al. Complementary effects of HDAC inhibitor 4-PB on gap junction communication and cellular export mechanisms support restoration of chemosensitivity of PDAC cells. Br. J. Cancer. 2007 Jan. 15; 96(1):73-81, Epub 2006 Dec. 12, реферат *

Also Published As

Publication number Publication date
WO2008095050A1 (en) 2008-08-07
US20160160286A1 (en) 2016-06-09
EP2107911A1 (en) 2009-10-14
NZ579048A (en) 2012-05-25
JP2014221049A (ja) 2014-11-27
KR101483805B1 (ko) 2015-01-16
AU2008210421A1 (en) 2008-08-07
US7838234B2 (en) 2010-11-23
EP2993473A1 (en) 2016-03-09
AU2014203224A1 (en) 2014-07-10
JP5670055B2 (ja) 2015-02-18
CN101657217B (zh) 2013-11-20
AU2008210421B2 (en) 2014-03-13
JP2010518811A (ja) 2010-06-03
US20090123374A1 (en) 2009-05-14
CN101657217A (zh) 2010-02-24
US20110053164A1 (en) 2011-03-03
EA200900927A1 (ru) 2010-04-30
US9128096B2 (en) 2015-09-08
EA201201640A1 (ru) 2013-09-30
KR20090106417A (ko) 2009-10-08
CA2677000A1 (en) 2008-08-07
EP2107911A4 (en) 2010-09-22

Similar Documents

Publication Publication Date Title
EA017985B1 (ru) Способы определения устойчивости рака к ингибиторам гистондеацетилазы
Goh et al. Chromosome 1q21. 3 amplification is a trackable biomarker and actionable target for breast cancer recurrence
JP6860476B2 (ja) 前立腺がん治療に関する方法及び組成物
US11549149B2 (en) Compositions and methods for detecting a mutant variant of a polynucleotide
US20230086722A1 (en) Methods for analysis of target molecules in biological fluids
WO2017040411A1 (en) Compositions and methods for detecting and diagnosing neoplasia
CN115698321A (zh) 用于血浆游离rna分析的多种方法
CN112292463A (zh) 用于预测癌症患者药物反应性的方法
US20250201370A1 (en) Methods of treating breast cancer
US12385920B2 (en) IL-6 signaling and breast cancer
WO2022183069A9 (en) Development of prmt-targeting therapy to enhance egfr-targeting drug efficacy in nsclc
US20080026481A1 (en) Molecular based two-marker assays that predict outcome of adenocarcinoma patients
US20250101524A1 (en) Compositions and methods for cell-free dna epigenetic gastrointestinal cancer detection and treatment
CN109642257A (zh) 药物疗法对癌的效果的预测方法
WO2022246000A1 (en) Compositions and methods for determining dna methylation level in cancer
US20230175072A1 (en) 3 flap okazaki fragments and uses thereof
Chakrabarti Molecular classification of endometrial cancers: The way forward
HK40087073A (zh) 用於血浆游离rna分析的多种方法
WO2022235701A1 (en) Gene expression profiling methods and compositions for determining cancer and treatment thereof
CN114258432A (zh) 用于预测癌症患者的药物反应性的方法
HK40070615A (en) Methods for predicting drug responsiveness in cancer patients
CN109486935A (zh) 作为骨质疏松症诊治靶标的aknad1基因
HK40040922A (en) Methods for predicting drug responsiveness in cancer patients

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

PD4A Registration of transfer of a eurasian patent in accordance with the succession in title
PD4A Registration of transfer of a eurasian patent in accordance with the succession in title
TC4A Change in name of a patent proprietor in a eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU